Status:
COMPLETED
Resveratrol in Patients With Non-alcoholic Fatty Liver Disease
Lead Sponsor:
University of Aarhus
Collaborating Sponsors:
The Ministry of Science, Technology and Innovation, Denmark
Aarhus University Hospital
Conditions:
Fatty Liver
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Non-alcoholic fatty liver disease (NAFLD) and fatty liver hepatitis (NASH) are very common in the Western world and strongly associated with obesity. No known effective treatment is known. From animal...
Detailed Description
Obesity is associated with non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) and recently, low-grade inflammation has been hypothesized to be the causative link. From animal studies...
Eligibility Criteria
Inclusion
- ALT ≥70 U/L for men and ≥45 U/L for women
- steatosis of the liver, assessed by ultrasonography
- one of the following:
- waist circumference ≥102 cm for men and ≥88 for women
- hypertension: BP ≥130/80 mmHg
- raised triglycerides ≥1,7 mmol/L
- reduced HDL cholesterol ≤1.0 mmol/L
- BMI ≥ 25 kg/m²
Exclusion
- weight \> 130 kg
- comorbidity such as diabetes, cancer, metabolic or coagulation disorder, or significant liver-, heart- or kidney disease
- MRI contraindication
- treatment with glucocorticoids or methotrexate
- alcohol intake \>20g/daily for men and \>12 for women
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT01464801
Start Date
September 1 2011
End Date
June 1 2015
Last Update
June 15 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital, Dept. of Hepatology and Gastroentology
Aarhus, Denmark, 8000